1. Scrip
  2. >>Business

Oxford’s PepGen Launches Into DMD With Next-Gen Oligonucleotide Platform

Aims To Challenge Sarepta

 
• By Andrew McConaghie

Arising from an Oxford and Cambridge university collaboration, the spin-out has selected Duchenne muscular dystrophy as the first target for its peptide platform.

Caroline Godfrey
PepGen's chief executive Caroline Godfrey.

New UK biotech company PepGen has raised $45m in Series A funding and has unveiled Duchenne muscular dystrophy (DMD) as the first target for its next-generation oligonucleotide platform.

Spun out two years ago from Oxford University with funding from Oxford Science Innovation (OSI), PepGen’s financing has been led...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.